RU2022106508A - Поливалентные и полиспецифические ох40-связывающие слитые белки - Google Patents
Поливалентные и полиспецифические ох40-связывающие слитые белки Download PDFInfo
- Publication number
- RU2022106508A RU2022106508A RU2022106508A RU2022106508A RU2022106508A RU 2022106508 A RU2022106508 A RU 2022106508A RU 2022106508 A RU2022106508 A RU 2022106508A RU 2022106508 A RU2022106508 A RU 2022106508A RU 2022106508 A RU2022106508 A RU 2022106508A
- Authority
- RU
- Russia
- Prior art keywords
- polyspecific
- polyvalent
- binding function
- function proteins
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Claims (1)
- Выделенный полипептид, который связывает OX40 и содержит множество доменов VHH, где каждый домен VHH связывает OX40, и где указанный полипептид является по меньшей мере тетравалентным.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662277027P | 2016-01-11 | 2016-01-11 | |
US62/277,027 | 2016-01-11 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018128629A Division RU2773052C2 (ru) | 2016-01-11 | 2017-01-11 | Поливалентные и полиспецифические ох40-связывающие слитые белки |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2022106508A true RU2022106508A (ru) | 2022-04-05 |
Family
ID=59275443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022106508A RU2022106508A (ru) | 2016-01-11 | 2017-01-11 | Поливалентные и полиспецифические ох40-связывающие слитые белки |
Country Status (13)
Country | Link |
---|---|
US (3) | US20170198051A1 (ru) |
EP (1) | EP3402507A4 (ru) |
JP (2) | JP7328761B2 (ru) |
KR (1) | KR20180098671A (ru) |
CN (1) | CN108883153A (ru) |
AU (2) | AU2017207318B2 (ru) |
BR (1) | BR112018013911A2 (ru) |
CA (1) | CA3009075A1 (ru) |
IL (2) | IL298686A (ru) |
MX (1) | MX2018008310A (ru) |
RU (1) | RU2022106508A (ru) |
SG (1) | SG11201805422WA (ru) |
WO (1) | WO2017123673A2 (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115093480A (zh) * | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
EP3402507A4 (en) * | 2016-01-11 | 2019-08-07 | Inhibrx, Inc. | MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS |
EP3487533A4 (en) * | 2016-07-20 | 2020-03-25 | IGM Biosciences, Inc. | MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF |
JP2019530434A (ja) * | 2016-08-05 | 2019-10-24 | ジェネンテック, インコーポレイテッド | アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法 |
CN117510643A (zh) * | 2016-09-23 | 2024-02-06 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
CA3058477A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
ES2966569T3 (es) * | 2017-12-29 | 2024-04-23 | Ap Biosciences Inc | Proteínas monoespecíficas y biespecíficas con regulación de puntos de control inmunitario para la terapia del cáncer |
CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
MX2021001703A (es) * | 2018-08-13 | 2021-04-19 | Inhibrx Inc | Polipeptidos de union a ox40 y sus usos. |
WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
JP2022504822A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
WO2020102647A1 (en) * | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
WO2020144164A1 (en) * | 2019-01-07 | 2020-07-16 | Bactolife Aps | Pathogen binding proteins |
TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥(蘇州)有限公司 | 結合pd-l1和ox40的雙特異性抗體 |
CN114616247A (zh) * | 2019-10-17 | 2022-06-10 | 江苏康宁杰瑞生物制药有限公司 | Ox40/pd-l1双特异性抗体 |
WO2021084104A1 (en) * | 2019-10-30 | 2021-05-06 | Bioinvent International Ab | Tetravalent antibody molecules |
JP2023507033A (ja) * | 2019-12-20 | 2023-02-20 | キソジ・バイオテクノロジー・インコーポレイテッド | ポリペプチド、タンパク質複合体及びそれを作製する方法 |
US20230295324A1 (en) * | 2020-06-30 | 2023-09-21 | Harbour Biomed (Shanghai) Co., Ltd | Ox40-targeted antibody, and preparation method therefor and application thereof |
EP3940931A1 (de) | 2020-07-14 | 2022-01-19 | Siemens Aktiengesellschaft | Verfahren zur herstellung eines rotors einer asynchronmaschine |
WO2022243341A1 (en) * | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
TW202334203A (zh) * | 2021-11-19 | 2023-09-01 | 德商皮里斯製藥有限公司 | 新穎的ox40及pd-l1特異性融合蛋白 |
WO2023109901A1 (en) * | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies and methods of use |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
EP1900753B1 (en) * | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
HUE029789T2 (en) * | 2005-05-06 | 2017-04-28 | Providence Health & Services - Oregon | Trimer OX40 Immunoglobulin Fusion Protein and Methods of Application |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
US20130332133A1 (en) * | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
LT2398498T (lt) | 2009-02-17 | 2019-01-10 | Ucb Biopharma Sprl | Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40 |
US8962807B2 (en) * | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
AU2011293253B2 (en) * | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN108610421B (zh) * | 2012-02-27 | 2022-08-19 | 阿布林克斯有限公司 | Cx3cr1结合多肽 |
US10011660B2 (en) | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
CN104684928A (zh) * | 2012-08-02 | 2015-06-03 | Jn生物科学有限责任公司 | 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白 |
WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
MX2015012059A (es) * | 2013-03-15 | 2016-01-12 | Merck Patent Gmbh | Anticuerpos biespecificos tetravalentes. |
MD20180107A2 (ru) | 2013-03-18 | 2019-06-30 | Biocerox Products B.V. | Гуманизированные анти-CD134 антитела (OX40) и их применение |
WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
EP3083687A2 (en) * | 2013-12-17 | 2016-10-26 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
EP3221360A1 (en) * | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
EP3402507A4 (en) * | 2016-01-11 | 2019-08-07 | Inhibrx, Inc. | MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS |
WO2018115003A2 (en) * | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
-
2017
- 2017-01-11 EP EP17738885.7A patent/EP3402507A4/en active Pending
- 2017-01-11 MX MX2018008310A patent/MX2018008310A/es unknown
- 2017-01-11 US US15/404,167 patent/US20170198051A1/en not_active Abandoned
- 2017-01-11 KR KR1020187022337A patent/KR20180098671A/ko unknown
- 2017-01-11 CN CN201780005939.9A patent/CN108883153A/zh active Pending
- 2017-01-11 WO PCT/US2017/013070 patent/WO2017123673A2/en active Application Filing
- 2017-01-11 JP JP2018535298A patent/JP7328761B2/ja active Active
- 2017-01-11 IL IL298686A patent/IL298686A/en unknown
- 2017-01-11 RU RU2022106508A patent/RU2022106508A/ru unknown
- 2017-01-11 SG SG11201805422WA patent/SG11201805422WA/en unknown
- 2017-01-11 CA CA3009075A patent/CA3009075A1/en active Pending
- 2017-01-11 AU AU2017207318A patent/AU2017207318B2/en active Active
- 2017-01-11 BR BR112018013911-4A patent/BR112018013911A2/pt unknown
-
2018
- 2018-07-10 IL IL260531A patent/IL260531B2/en unknown
-
2019
- 2019-03-07 US US16/295,332 patent/US11117972B2/en active Active
-
2021
- 2021-08-10 US US17/398,851 patent/US20220106397A1/en active Pending
-
2022
- 2022-09-28 JP JP2022154355A patent/JP2022185021A/ja active Pending
-
2024
- 2024-01-30 AU AU2024200551A patent/AU2024200551A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190263916A1 (en) | 2019-08-29 |
JP2019504062A (ja) | 2019-02-14 |
MX2018008310A (es) | 2019-01-28 |
EP3402507A2 (en) | 2018-11-21 |
IL260531A (ru) | 2018-08-30 |
JP7328761B2 (ja) | 2023-08-17 |
CA3009075A1 (en) | 2017-07-20 |
US11117972B2 (en) | 2021-09-14 |
EP3402507A4 (en) | 2019-08-07 |
AU2017207318B2 (en) | 2023-12-07 |
IL298686A (en) | 2023-01-01 |
WO2017123673A3 (en) | 2017-08-24 |
KR20180098671A (ko) | 2018-09-04 |
IL260531B2 (en) | 2023-05-01 |
US20170198051A1 (en) | 2017-07-13 |
US20220106397A1 (en) | 2022-04-07 |
RU2018128629A (ru) | 2020-02-13 |
IL260531B1 (en) | 2023-01-01 |
SG11201805422WA (en) | 2018-07-30 |
AU2024200551A1 (en) | 2024-02-22 |
RU2018128629A3 (ru) | 2020-06-16 |
AU2017207318A1 (en) | 2018-07-12 |
BR112018013911A2 (pt) | 2018-12-18 |
WO2017123673A2 (en) | 2017-07-20 |
CN108883153A (zh) | 2018-11-23 |
JP2022185021A (ja) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2022106508A (ru) | Поливалентные и полиспецифические ох40-связывающие слитые белки | |
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
EA201792176A1 (ru) | Полипептиды | |
EA201890712A1 (ru) | Антитела к про-/латентному миостатину и их применения | |
DK3411404T3 (da) | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
MA53248A (fr) | Anticorps anti-c5 à commutation ph améliorée | |
MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
EA201890078A1 (ru) | Антитело | |
MA52152A (fr) | Anticorps | |
CL2020002333A1 (es) | Anticuerpos anti-klk5 y métodos de uso. | |
BR112016015867A2 (pt) | anticorpos de elevada afinidade e resistentes à agregação com base nas regiões variáveis vl e no derivado vhh | |
MA44777A (fr) | Anticorps humanisés anti-basigine et leur utilisation | |
MA53105A (fr) | Activateurs de la réponse à une protéine non dépliée | |
DE112017003466A5 (de) | Detektion und Validierung von Objekten aus sequentiellen Bildern einer Kamera mittels Homographien | |
EA201992883A1 (ru) | АНТИТЕЛА К TrkB | |
DE112017003464A5 (de) | Detektion und Validierung von Objekten aus sequentiellen Bildern einer Kamera mittels Homographien | |
CO2020003260A2 (es) | Variantes de anticuerpo | |
DK3551188T3 (da) | Substituerede quinazolinsulfonamider som hæmmere af thioredoxin-interagerende protein (txnip) | |
DK3328887T3 (da) | Anti-GM-CSF antistoffer og anvendelser deraf | |
CO2021008755A2 (es) | Anticuerpo que se une a vegf y a il-1beta y métodos de utilización | |
KR20220035367A (ko) | 항-dll3 키메라 항원 수용체 및 이의 용도 | |
MA52083A (fr) | Formulation pour émulsion bitumineuse | |
DK3720296T3 (da) | Proteinrig pasta |